Avita Medical Inc (RCEL) Stock Price, Quote & News

Company Profile

AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also provides RECALL autologous cell harvesting device, which can treat areas of up to...

Industry: Medical Devices

Sector: Healthcare

Phone: 661 367 9170

Fax: 661 367 9180

Website: avitamedical.com

Address:

28159 Avenue Stanford, Suite 220, Valencia, United States

BeefStewart May. 13 at 9:31 PM

$RCEL via LinkedIn

0 · Reply

okeydokey_artichokey May. 13 at 6:53 PM

$RCEL Still early days, but it would be nice to see a small rev bump from Cohealyx. A great ecosystem, but I think near-term earnings gonna be choppy . glta

1 · Reply

BeefStewart May. 13 at 4:56 PM

$RCEL One day more.... one more day!

0 · Reply

All_City_Baby May. 13 at 2:39 PM

$RCEL

0 · Reply

scottgrant2 May. 12 at 9:06 PM

$RCEL earnings predictions?

1 · Reply

scottgrant2 May. 12 at 7:20 PM

$RCEL accumulating going on by some big fish..

1 · Reply

BeefStewart May. 11 at 5:39 PM

$RCEL what needs to happen for this to get to $20+ ?

1 · Reply

scottgrant2 May. 11 at 4:12 PM

$RCEL cup with handle forming

0 · Reply

BeefStewart May. 11 at 1:44 PM

$RCEL I suppose the other thing here is "squeeze potential." I don't rely on short squeezes. I do see how a low float stock that is heavily shorted could be a candidate for a short squeeze, though...

0 · Reply

BeefStewart May. 11 at 1:39 PM

$RCEL I haven't really followed the opening moves here before today. Is a 35ish thousand share trade a strong opening volume? I would guess so, given the avg daily volume is just over 220k....

0 · Reply

AVITA Medical Names Cary Vance as Chief Executive Officer

RCEL

Apr 29, 2026, 4:05 PM EDT - 14 days ago

AVITA Medical Announces TGA Certification in Australia and Medsafe WAND Listing in New Zealand for RECELL GO

RCEL

Apr 23, 2026, 4:10 PM EDT - 20 days ago

AVITA Medical to Announce First Quarter 2026 Financial Results

RCEL

Apr 15, 2026, 9:20 AM EDT - 4 weeks ago

AVITA Medical Founder Fiona Wood Honored with Lifetime Achievement Award by American Burn Association

RCEL

Apr 14, 2026, 7:45 AM EDT - 4 weeks ago

AVITA Medical Announces Positive Interim Results from Cohealyx® Study Demonstrating Accelerated Time to Skin Grafting

RCEL

Apr 13, 2026, 9:00 AM EDT - 4 weeks ago

AVITA Medical, Inc. Investigated by the Portnoy Law Firm

RCEL

Apr 7, 2026, 4:10 PM EDT - 5 weeks ago

AVITA Medical Showcases Acute Burn and Wound Care Portfolio at ABA 2026, Featuring New Cohealyx Data

RCEL

Feb 23, 2026, 4:15 PM EST - 2 months ago

AVITA Medical to participate at the TD Cowen 46th Annual Health Care Conference

RCEL

Feb 12, 2026, 4:01 PM EST - 3 months ago

AVITA Medical Reports Fourth Quarter and Full Year 2025 Financial Results

RCEL

Jan 13, 2026, 8:25 AM EST - 4 months ago

AVITA Medical: Pre-J.P. Morgan Update Highlights 2025 Revenue Growth, New Debt Facility, and 2026 Growth Outlook

RCEL

Jan 5, 2026, 4:05 PM EST - 4 months ago

AVITA Medical Announces Changes to its Board of Directors

RCEL

Dec 18, 2025, 4:15 PM EST - 5 months ago

AVITA Medical to Present at the 44th Annual J.P. Morgan Healthcare Conference

RCEL

Nov 24, 2025, 4:15 PM EST - 6 months ago

AVITA Medical to Present at the Piper Sandler 37ᵗʰ Annual Healthcare Conference

RCEL

Nov 3, 2025, 8:30 AM EST - 6 months ago

Data Presented at the 2025 Southern Region Burn Conference Reinforce RECELL® System as a Standard of Care in Acute Wound Treatment

RCEL

Oct 29, 2025, 4:15 PM EDT - 7 months ago

AVITA Medical to Announce Third Quarter 2025 Financial Results

RCEL

Oct 28, 2025, 4:30 PM EDT - 7 months ago

AVITA Medical Welcomes Support for RECELL® in Burns in Australia

RCEL

Oct 16, 2025, 6:15 PM EDT - 7 months ago

AVITA Medical Announces CEO Transition

RCEL

Oct 1, 2025, 8:30 AM EDT - 8 months ago

CMS New Technology Add-On Payment Expands Access to RECELL® for Patients with Non-Burn Acute Wounds

RCEL

Sep 9, 2025, 3:47 PM EDT - 8 months ago

AVITA Medical, Inc. Investors: Company Investigated by the Portnoy Law Firm

RCEL

Aug 21, 2025, 4:05 PM EDT - 9 months ago

AVITA Medical Announces September Investor Conference Participation

RCEL

Aug 12, 2025, 8:30 AM EDT - 9 months ago

AVITA Medical Successfully Completes Australian Equity Raise

RCEL

Aug 10, 2025, 7:00 PM EDT - 9 months ago

AVITA Medical to Host Investor Webinar Briefing

RCEL

Aug 7, 2025, 4:05 PM EDT - 9 months ago

AVITA Medical Reports Second Quarter 2025 Financial Results, Updates Full-Year Guidance, and Highlights Continued Clinical Innovation

RCEL

Jul 28, 2025, 4:05 PM EDT - 10 months ago

AVITA Medical to Announce Second Quarter 2025 Financial Results

RCEL

Jun 3, 2025, 8:00 PM EDT - 1 year ago

AVITA Medical's RECELL Platform Recognized for Surgical Innovation in 2025 MedTech Breakthrough Awards

RCEL

May 8, 2025, 4:03 PM EDT - 1 year ago

AVITA Medical Reports First Quarter 2025 Financial Results

RCEL

Apr 17, 2025, 4:05 PM EDT - 1 year ago

AVITA Medical to Announce First Quarter 2025 Financial Results

RCEL

Apr 9, 2025, 4:05 PM EDT - 1 year ago

AVITA Medical to Present Breakthrough Clinical Data in Burn and Wound Care at ABA 2025

RCEL

Apr 3, 2025, 4:03 PM EDT - 1 year ago

AVITA Medical Launches Cohealyx, Supporting Healing and Unlocking New Market Opportunity

RCEL

Mar 17, 2025, 4:05 PM EDT - 1 year ago

AVITA Medical Announces Exclusive Manufacturing and Distribution Agreements with Stedical Scientific

RCEL

Feb 26, 2025, 5:30 PM EST - 1 year ago

AVITA Medical to Present at TD Cowen's 45ᵗʰ Annual Health Care Conference

RCEL

Feb 13, 2025, 4:01 PM EST - 1 year ago

AVITA Medical Reports Fourth Quarter and Full Year 2024 Financial Results

RCEL

Jan 7, 2025, 10:12 PM EST - 1 year ago

AVITA Medical's shares sink 19% after another forecast cut

RCEL

Jan 7, 2025, 4:35 PM EST - 1 year ago

AVITA Medical Updates Expected Fourth Quarter and Full Year 2024 Revenue, Provides 2025 Financial Guidance

RCEL

Dec 23, 2024, 4:02 PM EST - 1 year ago

AVITA Medical Announces FDA Approval of RECELL GO mini, Optimizing Treatment for Smaller Wounds

RCEL

Dec 19, 2024, 5:05 PM EST - 1 year ago

AVITA Medical Announces FDA 510(k) Clearance for Cohealyx, Expanding its Addressable Market

RCEL

Dec 18, 2024, 4:08 PM EST - 1 year ago

AVITA Medical to Present at the 43rd Annual J.P. Morgan Healthcare Conference

RCEL

Nov 25, 2024, 4:02 PM EST - 1 year ago

AVITA Medical to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference

RCEL

Nov 12, 2024, 4:03 PM EST - 1 year ago

AVITA Medical Announces Exclusive Distribution Agreement to Expand to Australia and New Zealand

RCEL

BeefStewart May. 13 at 9:31 PM

$RCEL via LinkedIn

0 · Reply

okeydokey_artichokey May. 13 at 6:53 PM

$RCEL Still early days, but it would be nice to see a small rev bump from Cohealyx. A great ecosystem, but I think near-term earnings gonna be choppy . glta

1 · Reply

BeefStewart May. 13 at 4:56 PM

$RCEL One day more.... one more day!

0 · Reply

All_City_Baby May. 13 at 2:39 PM

$RCEL

0 · Reply

scottgrant2 May. 12 at 9:06 PM

$RCEL earnings predictions?

1 · Reply

scottgrant2 May. 12 at 7:20 PM

$RCEL accumulating going on by some big fish..

1 · Reply

BeefStewart May. 11 at 5:39 PM

$RCEL what needs to happen for this to get to $20+ ?

1 · Reply

scottgrant2 May. 11 at 4:12 PM

$RCEL cup with handle forming

0 · Reply

BeefStewart May. 11 at 1:44 PM

$RCEL I suppose the other thing here is "squeeze potential." I don't rely on short squeezes. I do see how a low float stock that is heavily shorted could be a candidate for a short squeeze, though...

0 · Reply

BeefStewart May. 11 at 1:39 PM

$RCEL I haven't really followed the opening moves here before today. Is a 35ish thousand share trade a strong opening volume? I would guess so, given the avg daily volume is just over 220k....

0 · Reply

scottgrant2 May. 11 at 2:29 AM

$MNKD $RCEL $SCPH

0 · Reply

BeefStewart May. 10 at 11:54 PM

$RCEL @scottgrant2 Absolutely about disciplined spending and deeper penetration into existing burn centers, as well as expanding the range of products (in the medium term) that will be available so that Avita can offer more comprehensive treatments for wound care. I believe the company has moved past it's lowest point, and I wouldn't be completely shocked if it gets acquired at a potentially frustrating valuation (for longer-term shareholders), similar to how $MNKD acquired $SCPH

0 · Reply

BeefStewart May. 9 at 6:31 PM

$RCEL wondering if this will go the route of $SCPH @OldManLogan any thoughts here?

1 · Reply

BeefStewart May. 8 at 5:31 PM

$RCEL I believe this is an $8+ stock in disguise.

1 · Reply

BeefStewart May. 8 at 3:58 PM

$RCEL Just an arbitrary ~10% drop in a week. Nothing to see here

0 · Reply

BeefStewart May. 8 at 3:47 PM

$RCEL @MITornado seems to be somewhat heavily shorted. The prevailing belief is that they won't turn the biz around. Perceptive Advisors stepped in to replace Orbimed. Perceptive previously helped $ADMA I believe Q1 numbers will be promising.

1 · Reply

MITornado May. 8 at 3:28 PM

$RCEL rejoined the party. Small potatoes really, but I like what I see. What am I missing? Why is this price so depressed?

0 · Reply

BeefStewart May. 8 at 3:00 PM

$RCEL I feel this is quite significant

1 · Reply

BeefStewart May. 8 at 2:51 PM

$RCEL

0 · Reply

BeefStewart May. 8 at 12:41 AM

$RCEL Anyone have any updated thoughts here?

1 · Reply

BeefStewart May. 7 at 11:11 PM

$RCEL 👽🥰

1 · Reply

BeefStewart May. 7 at 6:03 PM

$RCEL @DJarrett @GoldmanSlaps @techjerk I loaded up today Hoping for the best... .4.23 avg.

2 · Reply

Market Cap	134.50M
Revenue (ttm)	71.61M
Net Income (ttm)	-48.59M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-67.85%
Debt to Equity Ratio	-2.58

Volume	210,329
Avg Vol	210,530
Day's Range	N/A - N/A
Shares Out	30.78M
Stochastic %K	59%
Beta	1.90
Analysts	Sell
Price Target	$7.25